Journal Article10.1016/J.BBRC.2014.05.117
Cycloastragenol, a triterpene aglycone derived from Radix astragali, suppresses the accumulation of cytoplasmic lipid droplet in 3T3-L1 adipocytes.
Shifeng Wang,Chenxi Zhai,Qing Liu,Xing Wang,Zhenzhen Ren,Yuxin Zhang,Yanling Zhang,Qinghua Wu,Sheng-Nan Sun,Shiyou Li,Yanjiang Qiao +10 more
TL;DR: It is demonstrated that CAG was a potential therapeutic candidate for alleviating obesity and hyperlipidemia and elevated intracellular calcium played a vital role in suppressing adipocyte differentiation.
read more
About: This article is published in Biochemical and Biophysical Research Communications. The article was published on 18 Jul 2014. The article focuses on the topics: Cycloastragenol & Adipogenesis.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Terpenoids as Potential Geroprotectors.
Ekaterina Proshkina,Sergey Plyusnin,Sergey Plyusnin,Tatyana Babak,Ekaterina Lashmanova,Faniya Maganova,Liubov Koval,Liubov Koval,Elena Platonova,Elena Platonova,Mikhail Shaposhnikov,Alexey Moskalev,Alexey Moskalev +12 more
TL;DR: Terpenes and terpenoids are an underestimated source of potential geroprotectors that can effectively influence the mechanisms of aging and age-related diseases.
95
Molecular mechanism of down-regulating adipogenic transcription factors in 3T3-L1 adipocyte cells by bioactive anti-adipogenic compounds
Ajay Guru,Praveen Kumar Issac,Manikandan Velayutham,N.T. Saraswathi,Aziz Arshad,Jesu Arockiaraj +5 more
TL;DR: The cellular mechanism of 3T3-L1 fibroblast cells on potential anti-adipogenic herbal bioactive compounds is described.
79
Cycloastragenol: An exciting novel candidate for age‑associated diseases (Review)
TL;DR: According to existing studies and clinical trials, CAG is safe and has broad application prospects, however, further studies are required to fully understand its efficacy and potential adverse reactions, and to ensure the proper use of C AG is applied to treat diseases clinically.
Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor.
Xingping Duan,Qiang Meng,Changyuan Wang,Zhihao Liu,Qi Liu,Huijun Sun,Pengyuan Sun,Xiaobo Yang,Xiaokui Huo,Jinyong Peng,Kexin Liu +10 more
TL;DR: Investigation of the hepatoprotective effect of calycosin on attenuating triglyceride accumulation and hepatic fibrosis and the potential mechanism in murine model of NASH found it to protect against NASH via FXR activation.
57
Cycloastragenol improves hepatic steatosis by activating farnesoid X receptor signalling.
Ming Gu,Shiying Zhang,Yuanyuan Zhao,Jinwen Huang,Yahui Wang,Yin Li,Shengjie Fan,Li Yang,Guang Ji,Qingchun Tong,Cheng Huang +10 more
TL;DR: The data suggest that CAG ameliorates NAFLD via the enhancement of FXR signalling, a natural occurring compound in Astragali Radix, which stimulated FXR transcription activity.
44
References
Obesity as a medical problem
TL;DR: The global epidemic of obesity results from a combination of genetic susceptibility, increased availability of high-energy foods and decreased requirement for physical activity in modern society, and should be regarded as an epidemic that threatens global well being.
5.3K
Nile red: a selective fluorescent stain for intracellular lipid droplets.
TL;DR: The dye nile red, 9-diethylamino-5H- benzo[alpha]phenoxazine-5-one, is an excellent vital stain for the detection of intracellular lipid droplets by fluorescence microscopy and flow cytofluorometry and it exhibits properties of a near-ideal lysochrome.
Understanding Adipocyte Differentiation
TL;DR: Characterization of regulatory regions of adipose-specific genes has led to the identification of the transcription factors peroxisome proliferator-activated receptor-gamma and CCAAT/enhancer binding protein (C/EBP), which play a key role in the complex transcriptional cascade during adipocyte differentiation.
2.5K
Dyslipidemia in Obesity: Mechanisms and Potential Targets
TL;DR: An important link between obesity, the metabolic syndrome and dyslipidemia, seems to be the development of insulin resistance in peripheral tissues leading to an enhanced hepatic flux of fatty acids from dietary sources, intravascular lipolysis and from adipose tissue resistant to the antilipolytic effects of insulin.
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors.
TL;DR: The discovery and development of lovastatin — the first approved inhibitor of HMG-CoA reductase — and the clinical trials that have provided the evidence for the ability of drugs in this class to reduce the morbidity and mortality associated with cardiovascular disease are described.
894